C07K 2319/10
Containing a tag for extracellular membrane crossing
Official title: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
C07K2319/10 (Containing a tag for extracellular membrane crossing) appears on 790 US grants and 1,436 published applications in this corpus.
Search patents in C07K- Granted patents
- 790
- Published applications
- 1,436
- Assignees
- 703
- Inventors
- 2,613
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 6 | 0 |
| 1999 | 6 | 0 |
| 2000 | 5 | 0 |
| 2001 | 2 | 1 |
| 2002 | 10 | 6 |
| 2003 | 4 | 13 |
| 2004 | 5 | 13 |
| 2005 | 3 | 20 |
| 2006 | 4 | 21 |
| 2007 | 5 | 12 |
| 2008 | 5 | 22 |
| 2009 | 7 | 29 |
| 2010 | 11 | 28 |
| 2011 | 20 | 46 |
| 2012 | 14 | 44 |
| 2013 | 26 | 44 |
| 2014 | 37 | 57 |
| 2015 | 50 | 84 |
| 2016 | 51 | 95 |
| 2017 | 51 | 94 |
| 2018 | 55 | 94 |
| 2019 | 70 | 85 |
| 2020 | 51 | 105 |
| 2021 | 51 | 88 |
| 2022 | 62 | 95 |
| 2023 | 45 | 92 |
| 2024 | 56 | 94 |
| 2025 | 43 | 94 |
| 2026 | 23 | 60 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Utilization of gene targeting antibody fusion proteins to perform in vivo therapeutic gene editing22 Sep 2026US 12,741,035 B2Baylor College of Medicine
- Modified UBE3A gene for a gene therapy approach for Angelman syndrome15 Sep 2026US 12,734,250 B2University of South Florida
- Methods and compositions for treating skin disease with recombinant microorganisms11 Aug 2026US 12,702,684 B2Azitra Inc
- Anti-senescence compounds and uses thereof16 Jun 2026US 12,653,862 B2Cleara Biotech B.V.
- Cardiac-specific targeting-peptide (CTP), compositions, and uses thereof2 Jun 2026US 12,643,924 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Protein tyrosine phosphatase wedge domain peptide dimer for nervous system repair24 Sep 2026US 2026/0286322 A1NervGen Pharma Corp.
- Single fusion protein and pharmaceutical composition17 Sep 2026US 2026/0274910 A1Korea University Research and Business Foundation
- Monobodies selective to nras10 Sep 2026US 2026/0263609 A1New York University
- Nanostructured proteins and uses thereof10 Sep 2026US 2026/0265317 A1
- Glycosylated neuropeptide derivative including neuropeptide sequence and sugar chain, pharmaceutical composition, intranasal/nasal drop formulation, and use of glycosylated neuropeptide derivative10 Sep 2026US 2026/0265331 A1Tokyo University of Science Foundation
Most cited
By later US patents
- Expression and export technology of proteins as immunofusins276US 5,541,087 AFuji ImmunoPharmaceuticals Corporation · 1996
- Covalently-linked complexes and methods for enhanced cytotoxicity and imaging241US 5,169,933 ANeoRx Corporation · 1992
- Tat-derived transport polypeptides and fusion proteins213US 5,804,604 ABiogen, Inc. · 1998
- Fusion protein comprising tat-derived transport moiety177US 5,674,980 A1997
- Tat-derived transport polypeptide conjugates165US 5,747,641 A1998